Facebook Pixel image MagnaAngemon ACE BT14-037 | Digimon digimon Cards

digimon >Cards > MagnaAngemon ACE BT14-037

Icons of mtg
MagnaAngemon ACE BT14-037 image
setminmtgo
- 0.000.0 tix
Icons of mtg
NameMagnaAngemon ACE BT14-037 Edit card
TypeDigimon - ultimate vaccine archangel
DescriptionEffect [Hand][Counter] <Blast Digivolve> (One of your Digimon may digivolve into this card without paying the cost.) [On Play][When Digivolving] If you have 5 or fewer security cards, <Recovery +1 (Deck)>. Then, for the turn, 1 of your opponent's DigSee more
ArtistDigimon Card Game
SetDigimon card game exceed apocalypse [bt15] #BT14-037
WallpaperMagnaAngemon ACE BT14-037 Crop image Wallpaperdownload
ImageMagnaAngemon ACE BT14-037 Full hd imagedownload
⚠️

Tierlist

No Rank

Grade it yourself

Meta types

Edit card

Legality between formats

Edit card

About MagnaAngemon ACE BT14-037

MagnaAngemon ACE BT14-037, Digimon - ultimate vaccine archangel, designed by Digimon Card Game first released in May, 2024 in the set Exceed Apocalypse.

MagnaAngemon ACE BT14-037 would be particularly beneficial in a recovery-focused deck that aims to maintain a strong security presence while hindering opponents' attacks, especially in a meta where security control is crucial. Its ability to recover cards from the deck and reduce opponent's Digimon DP can create significant advantages in both defense and offense. While there are other powerful cards like Seraphimon or other recovery-focused Digimon that can provide similar benefits, MagnaAngemon's unique combination of recovery and DP reduction makes it a strong contender. Overall, it should see play in decks that prioritize security management and strategic control, especially in formats where maintaining a healthy security stack is vital.

Where to buy

Seller imageEbay.com

Visit store
Seller imagePrinting proxies

$ 0.75 Visit store

*This site contains affiliate links for which we may be compensated

Group by

Price alert ?

Alert me when price gets to

Price trend history

loading
Profile imageSign in and join the conversation

— Comments0

User profile image

Be the first to comment